Download Press Release: Shire to Acquire SARcode Bioscience, Expands Presence in Ohthalmology

Lexington, MA, US- March 25, 2013- Shire today announced that it will acquire SARcode Bioscience Inc., a privately held biopharmaceutical company based in Brisbane, California. The acquisition continues to build Shire’s presence in the ophthalmology therapeutic category and brings a new phase 3 compound- LIFITEGRAST- currently under development for the signs and symptoms of dry eye disease, into Shire’s portfolio. Shire anticipates launching LIFITEGRAST in the United States as early as 2016 pending a positive outcome of the phase 3 clinical development program and regulatory approvals. Shire is acquiring the global rights to LIFITEGRAST and will evaluate an appropriate regulatory filing strategy for markets outside of the United States.

> Click here to download the full press release

Shire is a Platinum Sponsor at the upcoming World Orphan Drugs Congress Asia 2013, held from 18-19 June at Grand Copthorne Waterfront Hotel, Singapore.

Leave a Reply

Your email address will not be published. Required fields are marked *